专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017192608A1 IMMEDIATE RELEASE DRUG FORMULATION COMBINING OPIOID AND NONOPIOID ANALGESICS WITH ABUSE DETERRENCE AND OVERDOSE PROTECTION 审中-公开
标题翻译：立即释放药物制剂与阿片类药物和非甾体类镇痛药物的不良反应和过量保护
公开(公告)号：WO2017192608A1
公开(公告)日：2017-11-09
申请号：PCT/US2017/030667
申请日：2017-05-02
申请人： KASHIV PHARMA LLC
发明人： VAKA, Siva, Ram Kiran , MEGHPARA, Kanji , DESAI, Dipen , PHUAPRADIT, Wantanee , SHAH, Navnit, H. , THONGSUKMAK, Atsawin
IPC分类号： A61K9/16 , A61K9/20 , A61K9/48 , A61K9/50 , A61K31/167 , A61K31/485
CPC分类号： A61K9/5073 , A61K9/1611 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2081 , A61K9/2086 , A61K9/48 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5084 , A61K31/167 , A61K31/485
摘要： The present disclosure provides solid immediate release (IR) dosage forms, including particulate and multi-particulate dosage forms, with abuse deterrent and overdose protection characteristics. In certain embodiments, the dosage form is multi¬ particulate, comprising: a first population of particulates comprising a therapeutically effective amount of at least one opioid embedded in a polymer matrix, an optional seal coat, a functional coat layer(s), and an over coat, wherein the functional coat layer(s) comprises a nonionic water-insoluble polymer, and a cationic polymer that dissolves at a pH of less than about 5; a second population of particulates comprising a therapeutically effective amount of acetaminophen (APAP) embedded in a polymer matrix, an optional seal coat, a functional coat layer(s), and an over coat, wherein the functional coat layer(s) comprises a cationic polymer that dissolves at a pH of less than about 5 and an optional nonionic water-insoluble polymer; and a third population of particulates comprising an alkaline agent, and an optional pH-stabilizing agent, wherein the alkaline agent raises the gastric pH when three or more dosage units are ingested, and the pH-stabilizing agent maintains the elevated pH. The dosage forms, including particulate and multi-particulate dosage forms, are designed to accomplish the desired combination of analgesia, abuse deterrence, and overdose protection.
摘要翻译：本公开提供了具有滥用威慑和过量保护特征的固体立即释放（IR）剂型，包括颗粒剂和多颗粒剂型。在某些实施方案中，剂型是多＆不; 其包含：第一群粒子，其包含治疗有效量的嵌入聚合物基质中的至少一种阿片样物质，任选的密封包衣，功能包衣层和外包衣，其中功能包衣层）包含非离子型水不溶性聚合物和在小于约5的pH下溶解的阳离子型聚合物; 包含嵌入聚合物基质中的治疗有效量的对乙酰氨基酚（APAP），任选的密封包衣，功能包衣层和外包衣的第二群颗粒，其中所述功能包衣层包含阳离子在小于约5的pH下溶解的聚合物和任选的非离子型水不溶性聚合物; 以及第三群颗粒，其包含碱性试剂和任选的pH稳定剂，其中当摄入三个或更多个剂量单位时，所述碱性试剂提高胃的pH，并且所述pH稳定剂保持提高的pH。包括颗粒剂和多颗粒剂型在内的剂型设计用于实现镇痛，滥用威慑和过量保护的所需组合。

2. 发明申请

WO2017059374A1 OVERDOSE PROTECTION AND ABUSE DETERRENT IMMEDIATE RELEASE DRUG FORMULATION 审中-公开
标题翻译：过量保护和滥用药物立即释放药物配方
公开(公告)号：WO2017059374A1
公开(公告)日：2017-04-06
申请号：PCT/US2016/055022
申请日：2016-09-30
申请人： KASHIV PHARMA LLC
发明人： SHAH, Navnit, H. , PHUAPRADIT, Wantanee , DESAI, Dipen , VAKA, Siva Ram Kiran , MEGHPARA, Kanji
IPC分类号： A61K9/16 , A61K9/20 , A61K9/48 , A61K9/50 , A61K31/485
CPC分类号： A61K9/5084 , A61K9/1641 , A61K9/2081 , A61K9/2086 , A61K9/48 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5073 , A61K9/5078 , A61K31/485
摘要： The presently disclosed subject matter provides a solid immediate release pharmaceutical multi-particulate dosage form containing at least two different populations of particulates. In certain embodiments, the immediate release pharmaceutical dosage forms contain at least three different populations of multi-particulates. Each population of particulates is designed for a specific function to accomplish the desired combination of abuse deterrence and overdose protection.
摘要翻译：目前公开的主题提供了含有至少两种不同粒子群体的立即快速释放药物多颗粒剂型。在某些实施方案中，立即释放的药物剂型含有至少三种不同的多颗粒群体。每个粒子群体都是为了实现滥用威慑和过量保护的所需组合而设计的。

3. 发明申请

WO2016187391A1 METHODS TO PREVENT TISSUE COLONIZATION OF PATHOGENS AND FOR TREATMENT OF BIOFILMS ON ANIMAL TISSUES 审中-公开
标题翻译：预防病原体组织结构和治疗动物组织生物膜的方法
公开(公告)号：WO2016187391A1
公开(公告)日：2016-11-24
申请号：PCT/US2016/033208
申请日：2016-05-19
申请人： HILLIARD, Carl , CAST, William R.
发明人： HILLIARD, Carl , CAST, William R.
IPC分类号： A01N31/16 , A01N31/08 , A01N25/22
CPC分类号： A01N55/00 , A01N33/12 , A61K8/416 , A61K8/585 , A61K8/66 , A61K9/0009 , A61K9/0017 , A61K9/0046 , A61K9/06 , A61K9/08 , A61K9/10 , A61K9/12 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5057 , A61K9/5063 , A61K31/695 , A61Q17/005 , A01N25/28 , A01N25/34
摘要： An antimicrobial product and methods of use are provided. The antimicrobial product includes a water-soluble antimicrobial organosilane (3-(trihydroxysilyl) propyldimethyloctadecyl ammonium chloride) and various additional adjuvant compounds, including anti-inflammatory medications, antiseptics, penetrants and/or detergents. An example delivery system including a microcapsule encasing the product is also described. Methods of use include embedding a delivery system within an article, such as bandages, inserts or wound coverings, the microcapsule containing the product which is released by a mechanism and at a time particular to the intended use of the article. The methods include topically treating a biofilm infection on an animal tissue substrate by disrupting existing microbial biofilm growth, penetrating existing biofilms, thereby killing microbes, and also through providing residual bonded organosilane, then killing persister cell microbes that through degrees of dormancy have escaped being killed.
摘要翻译：提供了抗微生物产品和使用方法。抗微生物产品包括水溶性抗微生物有机硅烷（3-（三羟基甲硅烷基）丙基二甲基十八烷基氯化铵）和各种其它助剂化合物，包括抗炎药物，防腐剂，渗透剂和/或洗涤剂。还描述了包括包装产品的微胶囊的示例递送系统。使用方法包括将输送系统嵌入物品（例如绷带，插入物或伤口覆盖物）中，所述微胶囊包含通过机构释放并且特别涉及制品的预期用途的产品。这些方法包括通过破坏现有的微生物生物膜生长，渗透现有的生物膜，从而杀死微生物，以及通过提供残留的结合的有机硅烷，然后杀死持续的休眠休眠程度被杀死的持续细胞微生物来局部地处理动物组织底物上的生物膜感染。

4. 发明申请

WO2016182737A1 AQUEOUS ENTERIC COATING COMPOSITION 审中-公开
标题翻译： AQUEOUS ENTERIC涂料组合物
公开(公告)号：WO2016182737A1
公开(公告)日：2016-11-17
申请号：PCT/US2016/029514
申请日：2016-04-27
申请人： SE TYLOSE USA, INC. , SHIN-ETSU CHEMICAL CO., LTD.
发明人： QUADIR, Anisul , OBARA, Sakae
IPC分类号： A61K9/48 , A61K47/44 , A61K38/08
CPC分类号： A61K9/282 , A61K9/2866 , A61K9/5015 , A61K9/5042
摘要： An aqueous enteric coating composition including hydroxypropylmethylcellulose, acetate succinate, and a basic amino acid.
摘要翻译：包含羟丙基甲基纤维素，乙酸琥珀酸酯和碱性氨基酸的水性肠溶包衣组合物。

5. 发明申请

WO2016178132A1 DUAL-CHAMBER PACK FOR EXTENDED RELEASE SUSPENSION COMPOSITIONS 审中-公开
标题翻译：用于扩展释放悬架组合物的双室包装
公开(公告)号：WO2016178132A1
公开(公告)日：2016-11-10
申请号：PCT/IB2016/052486
申请日：2016-05-02
申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED
发明人： BHARGAVA, Rahul , MITTAL, Bhupesh Kumar , RAMARAJU, Kalaiselvan , KUMAR, Ashish
IPC分类号： A61J1/14 , A61K9/14 , B65D25/08
CPC分类号： A61J1/2093 , A61J1/1418 , A61J1/18 , A61J1/2006 , A61J1/2027 , A61K9/0095 , A61K9/10 , A61K9/145 , A61K9/5015 , A61K9/5042 , A61K9/5047 , A61K9/5084 , A61K9/5089 , A61K31/155 , A61K31/165 , A61K31/43 , A61K31/4439 , A61K31/522 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/38
摘要： The present invention relates to a dual-chamber pack comprising a first chamber prefilled with a suspension base and a second chamber prefilled with a powder for suspension comprising an active ingredient, wherein upon activation of the dual-chamber pack, the contents of both the chambers are mixed to form an extended release suspension composition which is characterized by having no substantial change in the in-vitro dissolution release profile of the active ingredient upon storage for at least seven days.
摘要翻译：本发明涉及一种双室包装，其包括预充满悬架基部的第一室和预先填充有用于悬浮液的粉末的第二室，其包括活性成分，其中在激活双室包装时，两室的内容物混合以形成延长释放悬浮液组合物，其特征在于在储存至少7天时活性成分的体外溶出释放曲线没有显着变化。

6. 发明申请

WO2016132220A1 CONTROLLED RELEASE ORAL DOSAGE FORM OF GABA RECEPTOR AGONIST 审中-公开
标题翻译：控制释放GABA受体激动剂的口服剂型
公开(公告)号：WO2016132220A1
公开(公告)日：2016-08-25
申请号：PCT/IB2016/000260
申请日：2016-02-19
申请人： OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
发明人： MEYER, Glenn, A. , FRANCO, Cristian, R. , FISCHBEIN, Gustavo, A. , AGUILAR, Alejandro, A. , WRIGHT, Claude, E. , AIKMAN, Mark, S.
IPC分类号： A61K9/00 , A61K31/197 , A61P25/08
CPC分类号： A61K31/197 , A61K9/0004 , A61K9/0053 , A61K9/006 , A61K9/145 , A61K9/146 , A61K9/20 , A61K9/2031 , A61K9/2866 , A61K9/4866 , A61K9/5042 , A61K31/222 , A61K31/325
摘要： The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABA B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA B receptor agonist.
摘要翻译：本发明提供了能够提供包含在其核心中的GABA B受体激动剂的受控释放的简单且改进的剂型。本发明还提供了施用剂型和治疗对GABA B受体激动剂具有治疗反应性的病症的方法。

7. 发明申请

WO2016077629A1 METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME 审中-公开
标题翻译：用PRADER-WILLI综合征或史密斯综合征治疗子宫的方法
公开(公告)号：WO2016077629A1
公开(公告)日：2016-05-19
申请号：PCT/US2015/060455
申请日：2015-11-12
申请人： ESSENTIALIS, INC.
发明人： COWEN, Neil M.
IPC分类号： A61K9/22 , A61K31/54 , A61K31/549 , C07D285/22
CPC分类号： A61K31/549 , A61K9/00 , A61K9/0004 , A61K9/2054 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K31/137 , A61K31/155 , A61K31/551 , A61K38/27 , A61K45/06 , A61K2300/00 , C07D285/18 , C07D285/22
摘要： Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering K ATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
摘要翻译：提供某些钾ATP（KATP）通道开放剂（任选与生长激素组合）立即或长期给予受试者，以在治疗涉及KATP的疾病或病症中获得新颖的药效学，药代动力学，治疗学，生理学，代谢和组合结果通道。还提供了实现这些结果并降低治疗个体的不良反应发生率的药物制剂，给药方法和KATP通道开放剂的给药方法。还提供了将KATP通道开放剂与其他药物（例如与生长激素组合）共同治疗以治疗人和动物疾病（例如，Prader-Willi综合征（PWS），Smith-Magenis综合征（SMS））和类似。

8. 发明申请

WO2015089420A1 CONTROLLED RELEASE DOSAGE FORM FOR ONCE DAILY ADMINISTRATION OF DIMETHYL FUMARATE 审中-公开
标题翻译：受控释放的剂型用于日常管理二甲基纤维素
公开(公告)号：WO2015089420A1
公开(公告)日：2015-06-18
申请号：PCT/US2014/070058
申请日：2014-12-12
申请人： BIOGEN IDEC MA INC.
发明人： ZAWANEH, Peter , KARKI, Shyam, B. , KAUFMAN, Michael , LEUNG, Cheuk-Yui , DONG, Jinquan , QUAN, Ernest , VASUDEVAN, Kalyan
IPC分类号： A61K9/00 , A61K9/20 , A61K9/28 , A61K9/48 , A61K9/50 , A61K31/215 , A61K9/24 , A61K9/32 , A61K9/36 , A61K9/58 , A61K9/62 , A61P25/00
CPC分类号： A61K9/0065 , A61K9/0004 , A61K9/14 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2086 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886 , A61K9/4808 , A61K9/5026 , A61K9/5031 , A61K9/5042 , A61K9/5047 , A61K9/5073 , A61K31/22
摘要： A controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo , or a pharmaceutically acceptable salt thereof or combinations thereof.
摘要翻译：一种含有富马酸monomcthyl的受控释放剂型，可以在体内代谢成富马酸monomcthyl的化合物或其药学上可接受的盐或其组合，其中富马酸monomcthyl，体内可代谢成富马酸monomcthyl的化合物或其药学上可接受的盐或其组合被递送至受试者。还提供了通过口服施用含有富马酸monomcthyl，可以在体内代谢成富马酸monomcthyl的化合物或其药学上可接受的盐或其组合的控制释放剂型来治疗疾病或病症（例如多发性硬化症）的方法，其中富马酸单子酯，可以在体内代谢成富马酸单甲酯的化合物，或其药学上可接受的盐或其组合。

9. 发明申请

WO2015003662A9 TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND APPLICATION THEREOF 审中-公开
标题翻译：传统中医药组合物及其制备及应用
公开(公告)号：WO2015003662A9
公开(公告)日：2015-04-23
申请号：PCT/CN2014082105
申请日：2014-07-11
申请人： TASLY PHARMACEUTICAL GROUP CO
发明人： YAN XIJUN , WU NAIFENG , YAN KAIJING , YE ZHENGLIANG , ZHANG SHUNNAN , ZHOU LIHONG , ZHANG WENSHENG , DONG HAI OU , ZHENG YONGFENG , FAN LIJUN
IPC分类号： A61K36/537 , A61K9/20 , A61K31/045 , A61K31/343 , A61K31/58 , A61K31/7048 , A61K36/258 , A61P9/10
CPC分类号： A61K36/537 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5089 , A61K31/045 , A61K31/11 , A61K31/192 , A61K31/216 , A61K31/222 , A61K31/343 , A61K31/704 , A61K36/258 , A61K2300/00
摘要： A traditional Chinese medicine composition and a preparation thereof, and in particular, a micro drop pill. The traditional Chinese medicine composition comprises 50.0% to 99.9% of salvia miltiorrhiza and Panax notoginseng extract and 0.1% to 50.0% of borneol (by weight percentage). The salvia miltiorrhiza and Panax notoginseng extract comprises the following components (by weight percentage): salvianic acid A: salvianolic acid T: protocatechuic aldehyde: salvianolic acid D: rosmarinic acid: salvianolic acid B: salvianolic acid A: Notoginsenoside R1: ginsenoside Rg1: ginsenoside Re: ginsenoside Rb1: ginsenoside Rd: dihydrotanshinoneI: tanshinone I: cryptotanshinone: tanshinone IIΑ = (2-5): (0.5-1.9): (1.1-3): (0.2-1.2): (0.2-1): (0.5-2): (0.5-2): (0.2-1): (1.5-4): (0.1-0.5): (1-3.9): (0.1-1): (0.01-0.05): (0.05-0.1): (0.02-0.1): (0.1-0.5). A preparation method for the micro drop pill comprises vibration dropping, air cooling, and the like. The method can be used to manufacture drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity. The composition has an effect of treating acute myocardial ischemia and acute myocardial infarction.
摘要翻译：一种中药组合物及其制剂，特别是微滴丸。中药组合物含有丹参和三七提取物50.0％〜99.9％，冰片0.1％〜50.0％（按重量百分比计）。丹参和三七提取物含有以下组分（重量百分数）：salvianic acid A：salvianolic acid T：原儿茶醛：salvianolic acid D：迷迭香酸：salvianolic acid B：salvianolic acid A：三七皂苷R1：人参皂甙Rg1：人参皂甙 Re：人参皂苷Rb1：人参皂苷Rd：二氢丹参酮I：丹参酮I：隐丹参酮：丹参酮IIA =（2-5）：（0.5-1.9）：（1.1-3）：（0.2-1.2）：（0.2-1） -2）：（0.5-2）：（0.2-1）：（1.5-4）：（0.1-0.5）：（1-3.9）：（0.1-1）：（0.01-0.05）：（0.05-0.1 ）：（0.02-0.1）：（0.1-0.5）。微滴丸的制备方法包括振动降落，空气冷却等。该方法可用于制造具有高药物负载能力的滴丸，包衣药丸和滴丸胶囊。该组合物具有治疗急性心肌缺血和急性心肌梗死的作用。

10. 发明申请

WO2015031756A1 NOVEL 2,4-DINITROPHENOL FORMULATIONS AND METHODS USING SAME 审中-公开
标题翻译：新型2,4-二硝基苯酚配方及其使用方法
公开(公告)号：WO2015031756A1
公开(公告)日：2015-03-05
申请号：PCT/US2014/053406
申请日：2014-08-29
申请人： YALE UNIVERSITY
发明人： SHULMAN, Gerald I. , PERRY, Rachel Jamison
IPC分类号： A61K31/06 , A61P1/16 , A61K9/22
CPC分类号： A61K31/06 , A61K9/0053 , A61K9/501 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K45/06
摘要： The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (DNP). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.
摘要翻译：本发明包括2,4-二硝基苯酚（DNP）的低剂量和持续释放制剂。本发明的组合物可用于预防或治疗有需要的受试者中的疾病或病症，例如非酒精性脂肪肝疾病，非酒精性脂肪性肝炎，胰岛素抵抗和/或糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式